Detectability of Plasma-Derived Circulating Tumor DNA Panel in Patients Undergoing Primary Treatment for Uveal Melanoma
Open Access
- 16 December 2022
- journal article
- research article
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 63 (13) , 17
Abstract
Purpose: To investigate the presence of plasma circulating tumor DNA (ctDNA) in patients with uveal melanoma during and after primary tumor treatment. Methods: Detectability and variant allele frequency of ctDNA were assessed using a 129-oncogene panel using next-generation deep sequencing and hybridization capture in 69 patients with uveal melanoma undergoing primary treatment with enucleation (n = 8, during surgery) or plaque brachytherapy (n = 61; postoperative day 0, 1, 2, or 3). Follow-up assessments were performed in 39 patients over a median of 21 months (range, 3.2–31.9 months) of follow-up. Correlations between genomic data and disease parameters were performed. Results: Overall, ctDNA was detectable in 20 of 69 patients with uveal melanoma (28.9%) during the perioperative period. On the day of enucleation, ctDNA was detected in two of eight patients (25%). In patients undergoing brachytherapy, ctDNA was significantly more detectable on postoperative days 2 or 3 compared with postoperative day 0 or 1 (32.4% vs 0.0%; P = 0.0015). Patients with follow-up ctDNA that became detectable or had an increased variant allele frequency were significantly more likely to develop metastasis compared with patients with follow-up ctDNA that became undetectable or decreased variant allele frequency (P = 0.04). In patients with detectable vs. undetectable ctDNA, there was no significant difference in tumor size, stage or location. Conclusions: ctDNA is significantly more detectable at 48 to 72 hours after plaque brachytherapy compared with less than 48 hours. ctDNA can be detected during enucleation. Relative increases in ctDNA levels may herald the development of clinically apparent metastases.Keywords
This publication has 20 references indexed in Scilit:
- Cell-free DNA Analysis in CancerNew England Journal of Medicine, 2019
- Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal MelanomaJCO Precision Oncology, 2018
- Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patientsOncotarget, 2018
- Liquid Biopsies: Genotyping Circulating Tumor DNAJournal of Clinical Oncology, 2014
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human MalignanciesScience Translational Medicine, 2014
- Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanomaInternational Journal of Cancer, 2013
- Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNANature, 2013
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast CancerNew England Journal of Medicine, 2013
- Ultradeep sequencing detects GNAQ and GNA11 mutations in cell‐free DNA from plasma of patients with uveal melanomaCancer Medicine, 2013
- Pyrophosphorolysis-Activated Polymerization Detects Circulating Tumor DNA in Metastatic Uveal MelanomaClinical Cancer Research, 2012